Ocular Therapeutix, Inc. (NASDAQ: OCUL) will present its strategic outlook for 2025 at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, in San Francisco, CA. The presentation will include an update on the enrollment status of the SOL-R trial, which is the company's second registrational trial of AXPAXLI™ for the treatment of wet age-related macular degeneration (wet AMD).
Pravin U. Dugel, MD, Executive Chairman, President and CEO of Ocular Therapeutix, will lead the presentation, offering insights into the future opportunities for AXPAXLI and providing a general corporate overview. The presentation is scheduled for 5:15 PM PT.
AXPAXLI for Wet AMD
AXPAXLI™ (axitinib intravitreal injection), also known as OTX-TKI, is Ocular Therapeutix's product candidate for retinal diseases. It utilizes the ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. Currently, AXPAXLI is undergoing Phase 3 clinical trials for wet AMD.
Ocular Therapeutix Pipeline
Ocular Therapeutix leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. Their pipeline also includes PAXTRAVA™ (travoprost intracameral injection or OTX-TIC), which is in Phase 2 clinical trial for open-angle glaucoma or ocular hypertension.
The live presentation can be accessed on the Events and Presentations section of the Investor Relations page of the Ocular Therapeutix website.
